gsk (Celgene)
86
Structured Review
Celgene
gsk
Gsk, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gsk/gsk/pm42299486-137-9-33
Average 86 stars, based on 1 article reviews
Gsk, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gsk/gsk/pm42299486-137-9-33
Average 86 stars, based on 1 article reviews
gsk - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. Article Snippet: Article Title: Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma. Article Snippet: He also serves as a 498 consultant for: Abbvie, Amgen, Article Title: The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D Article Snippet: HE declares a consulting or advisory role for Article Title: Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma Article Snippet: Conflict-of-interest disclosure: S.Z.U. is the Chair of the American Society of Hematology (ASH) Research Collaborative Multiple Myeloma Research Network; a member of the ASH Research Collaborative Multiple Myeloma Scientific Research Project Team; a member of the ASH Research Collaborative Data Quality Project Team; reports research funding from AbbVie, Amgen, Bristol Myers Squibb (BMS)/Celgene, Gracell, Article Title: Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers Article Snippet: 1 Genetic evidence against clonotypic B-lymphocytes as 1 reservoir of plasma-cell cancers 2 3 Running title: Clonal lymphopoiesis in myeloma and AL amyloidosis 4 5 Authors: Carmen Gonzalez1, Juan-Jose Garces1,2, Hector Gracia1, Camila 6 Guerrero1, Mattia D'Agostino3, Alejandro Medina-Herrera4, Mario Nuvolone5,6, 7 Noemi Puig4, Maria-Teresa Cedena7, Marta Lasa1, Diego Alignani1, Aitziber 8 Lopez1, Sarai Sarvide1, Paula Aguirre-Ruiz1, José Maria Lamo-Espinosa1, 9 Felipe Prosper1, Paula Rodriguez-Otero1, Jose A Martinez-Climent1, Francesca 10 Lattarulo5,6, Alice Nevone5,6, Margherita Massa6, Giovanni Palladini5,6, 11 Giuseppe Bertuglia3, Francesca Gay3, Laura Rosiñol8, Ramon Garcia-Sanz4, 12 Joaquin Martinez-Lopez7, Maria-Victoria Mateos4, Juan-Jose Lahuerta7, Joan 13 Blade8, Jesus F. San-Miguel1, Bruno Paiva1, on behalf of the PETHEMA/GEM 14 cooperative group9.. 15 16 Affiliations: (1) Cancer Center Clinica Universidad de Navarra (CCUN) , 17 Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), 18 IDISNA, CIBER-ONC CB16/12/00369 and CB16/12/00489, Pamplona, Spain; 19 (2) Department of Medicine, Myeloma Service, Memorial Sloan Kettering 20 Cancer Center; (3) Division of Hematology, AOU Città della Salute e della 21 Scienza di Torino, University of Torino and Department of Molecular 22 Biotechnology and Health Sciences, University of Torino, Torino, Italy; 4) 23 Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), 24 CIBER-ONC, Salamanca, Spain; (5) Department of Molecular Medicine, 25 University of Pavia, Pavia, Italy; (6) Amyloidosis Research and Treatment 26 Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; (7) Hematology 27 Department, Hospital Universitario 12 de Octubre, CIBER-ONC, Instituto de 28 Investigación IMAS12, Madrid, Spain; (8) Amyloidosis and Myeloma Unit, 29 Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS; (9) Oficinas 30 centrales de PETHEMA, Madrid, Spain.. 31 32 33 D ow nloaded from http://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BC D -25-0102/3747074/bcd-25-0102.pdf by guest on 15 M arch 2026 2 Disclosure of conflicts of interest: Mattia D'Agostino reports honoraria from 34 Sanofi, Glaxo-Smith-Kline, Janssen; serving on the advisory boards for Sanofi, 35 Glaxo-Smith-Kline, Bristol-Myers-Squibb, Janssen, Adaptive biotechnologies; 36 received research support by Janssen. Article Title: The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D. Article Snippet: HE declares a consulting or advisory role for Derivative Assay:Article Title: Real-world evidence of measurable residual disease assessment in multiple myeloma Article Snippet: B.P. reports receiving consultancy fees from BMS-Celgene, GSK, Johnson & Johnson, Roche, and Sanofi; research funding from AstraZeneca, BeiGene, BMS, GSK, Roche, and Sanofi; and honoraria from Adaptive, Amgen, Becton Dickinson Biosciences, BMS-Celgene, GSK, Johnson & Johnson, Roche, and Sanofi. .. F.d.A. reports receiving honoraria derived from lectures and participation in advisory boards from Johnson & Johnson, BMS-Celgene, Amgen, |